🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "significant breakthrough" in the battle against increasingly resistant strains of the infection, according to researchers.

An International Challenge

Gonorrhoea infections are on the rise worldwide, with figures suggesting in excess of 82 million instances annually. Especially elevated rates are observed in the African continent and nations within the WHO's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary advancement in the face of increasing worldwide cases, the spread of superbugs and the highly restricted therapeutic options at this time.”

Medical experts are deeply concerned about the surge in antibiotic-resistant strains. The global health body has designated it as a "priority pathogen". Recent surveillance revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Secure Clearance

Zoliflodacin, alternatively called a brand name, was approved by the US Food and Drug Administration in recent days for use against gonorrhoea. This infection can lead to major issues, including the inability to conceive. Experts anticipate that specific application of this new drug will help slow the emergence of superbugs.

Gepotidacin, created by the drugmaker GlaxoSmithKline, was also approved in concurrent days. This drug, which is employed against urinary tract infections, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to develop it.

“This milestone represents a major breakthrough in the therapy of superbug gonorrhoea, which until now has been outpacing medical innovation.”

Clinical Trial Data and Worldwide Availability

As per results released by a prominent scientific publication, the new drug successfully treated the vast majority of cases of the STI. This puts it on an comparable level with the typical regimen, which uses two antibiotics. The study involved nearly 1,000 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the authority to license and sell the drug in a wide range of low-income and middle-income countries.

Medical professionals directly involved have voiced optimism. Access to a one-pill regimen such as this is described as a "revolutionary step" for gonorrhoea control. This is considered essential to reduce the burden of the illness for people and to halt the transmission of untreatable gonorrhoea around the world.